AMLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amylyx Pharmaceuticals Inc (AMLX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising catalysts like the Phase 3 LUCIDITY trial and positive analyst sentiment, the recent price drop, insider selling, and weak financial performance suggest caution. Given the lack of immediate trading signals and the absence of clear upward momentum, holding off on investment until further clarity or better entry points is recommended.
The technical indicators are mixed. The MACD is negative and expanding, suggesting bearish momentum. RSI is neutral at 42.51, and the stock is trading near key support levels (S1: 13.852). Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the overall trend lacks strong upward momentum.
Analysts are optimistic, with multiple Buy ratings and price target increases, including a high target of $
The Phase 3 LUCIDITY trial for avexitide is a significant long-term growth driver.
The company has a strong cash runway into 2028, supporting its R&D and commercialization efforts.
Insiders are selling heavily, with a 2291.45% increase in selling activity over the last month.
Financial performance is weak, with declining EPS (-45.45% YoY) and net income (-12.11% YoY).
Recent price performance is poor, with a 6.31% drop in regular market trading.
In Q4 2025, the company reported a net income loss of $32.99 million, down 12.11% YoY, and an EPS of -$0.30, down 45.45% YoY. Gross margin was 0, reflecting no revenue generation yet. However, the company has $317 million in cash and a cash runway into 2028, providing financial stability for its ongoing trials.
Analysts are bullish on AMLX, with multiple Buy ratings and price target increases. H.C. Wainwright raised its target to $34, citing confidence in the LUCIDITY trial and avexitide program. Stifel initiated coverage with a $21 target, highlighting the potential of avexitide in post-bariatric hypoglycemia. BofA and Mizuho also raised their targets to $19, reflecting optimism about the company's pipeline.
